Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 67

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

The report 'Placenta Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview 6
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment 13
Assessment by Mechanism of Action 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development 18
Alteogen Inc 18
Chengdu Kanghong Pharmaceuticals Group Co Ltd 18
Formycon AG 18
Lupin Ltd 19
Regeneron Pharmaceuticals Inc 20
ThromboGenics NV 20
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles 22
(aflibercept + nesvacumab) - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
aflibercept - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
aflibercept biosimilar - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
aflibercept biosimilar - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
aflibercept biosimilar - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
aflibercept SR - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
conbercept - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SL-186 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
SL-188 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
THR-317 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ziv-aflibercept - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products 52
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products 53
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones 54
Featured News & Press Releases 54
Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 54
May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 55
May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 56
Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 57
Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 58
Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 58
Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 59
May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 60
May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 61
Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 62
Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62
Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 63
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 64
Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 64
Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Alteogen Inc, H2 2017 18
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 18
Pipeline by Formycon AG, H2 2017 19
Pipeline by Lupin Ltd, H2 2017 19
Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 20
Pipeline by ThromboGenics NV, H2 2017 21
Dormant Projects, H2 2017 52
Discontinued Products, H2 2017 53

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16
  • United States Protein Biochip Market Report 2017
    Published: 21-Nov-2017        Price: US 3800 Onwards        Pages: 95
    In this report, the United States Protein Biochip market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of ......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Antibody Services Market 2017 Forecast to 2022
    Published: 20-Nov-2017        Price: US 4880 Onwards        Pages: 124
    Antibody services include competitively priced packages and purification options for antibody production. Service Providers offer support for different types and steps of antibody production—from peptide design, synthesis, and carrier protein conjugation to animal immunization, serum collection, or hybridoma fusion, titer analysis, and final antibody purification. They also immunize with recombinant proteins or protein fragments provided by the customers(or expressed and purified in labs using c......
  • Global Oligonucleotide Pool Library Market Professional Survey Report 2017
    Published: 20-Nov-2017        Price: US 3500 Onwards        Pages: 111
    This report studies Oligonucleotide Pool Library in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Agilent - Eurogentec S.A - Sigmaaldrich - Illumnia......
  • Global Microbial Growth Media Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 105
    In this report, the global Microbial Growth Media market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Microbial Growth Media for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe -......
  • China Procalcitonin Antibody Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
    Published: 17-Nov-2017        Price: US 4480 Onwards        Pages: 122
    Procalcitonin (PCT) is a 116 amino acid residue protein with a molecular weight of approximately 13kDa. Procalcitonin is a peptide hormone mainly produced by the C cells of the thyroid and certain endocrine cells of the lung. Under normal expression conditions, procalcitonin is immediately cleaved into three specific fragments, an N terminal residue, calcitonin and katacalcin. It can be expressed in E. coli Scope of the Report: This report focuses on the Procalcitonin Antib......
  • Global and Regional Oligonucleotide Pool Library Market Research Report 2017
    Published: 16-Nov-2017        Price: US 3500 Onwards        Pages: 153
    Summary Oligo pools, which are high diversity collections of oligonucleotides, are utilized to generate CRISPR guide RNA (sgRNA) libraries for cloning into expression vectors. Accuracy and uniformity of oligo synthesis are critical to ensure specificity of targeting and oligo representation.This report studies the Oligonucleotide Pool/Library market, the Oligonucleotide Pool/Library is the array of the Oligonucleotide. They are used for gene chips, electrophoresis and so on.......
  • Global Biobanking Market Professional Survey Report 2017
    Published: 15-Nov-2017        Price: US 3500 Onwards        Pages: 119
    This report studies Biobanking in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Beckman Coulter - Thermo Fisher - Panasonic - Sigma-Aldrich - SOL ......
  • United States Ion Indicators Market Report 2017
    Published: 15-Nov-2017        Price: US 3800 Onwards        Pages: 103
    In this report, the United States Ion Indicators market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of I......
  • Global DNA Forensic Market Research Report 2017
    Published: 14-Nov-2017        Price: US 2900 Onwards        Pages: 119
    In this report, the global DNA Forensic market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of DNA Forensic in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs